Importantly, inhibition of FAK, either by Defactinib treatment or siFAK, significantly impaired T-cell-mediated killing of BT-549 cancer cells (Figure 7B–E), indicating that FAK inhibition enhances immune evasion by upregulating PD-L1. Here, CD274 is linked to cancer.